Clinical Research Trials

Philadelphia FIGHT (FIGHT) was founded as the Community-Based Research Initiative on AIDS. Clinicians at FIGHT continue to be involved in a number of studies. Below are a list of clinical research trials at FIGHT.

Y-HEP Health Center | Jonathan Lax Health Center


The following clinical trials are ongoing at the Lax Center and currently enrolling patients:

There are no trials enrolling new patients at this time. Please feel free to browse the Research Department bulletin board for other local research opportunities during your next visit to the Lax Center.

The following clinical trials are ongoing at the Lax Center but not enrolling new patients:

Beyond Antiretroviral Treatment: Reducing Proviral HIV DNA with Interferon-α Immunotherapy (BEAT-HIV): A randomized, multi-site, open-label study to assess the effectiveness of Peg-IFN-α2b in decreasing the levels of cell-associated, integrated viral DNA in HIV chronic infection

Merck Peripheral Blood Draw Study: A non-interventional trial intended to collect peripheral blood from patients undergoing treatment for chronic HIV infections

Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed Dose Combination Once Daily for Pre-Exposure Prophylaxis (PrEP)

Trial Number: GS-US-412-2055

Description: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women who have Sex with Men and are at Risk of HIV-1 Infection

Open Label, HIV/HCV Co-Infection study of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment in Subjects who Switch to Elvitegravir/ Cobicistat/Emtricitabine/Tenofovir Alafenamide

Trial Number: GS-US-366-1992
Description: A Phase 3b Randomized, Open-label, Controlled Study of the Efficacy, Safety and Tolerability of 12 Weeks of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co infected Subjects who Switch to Elvitegravir/ Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) prior to LDV/SOF HCV Treatment, the HIV/HCV Co-STARs study (Co-infection treatment with Single Tablet Antiviral Regimens)

Double-Blind Study to Evaluate Safety and Efficacy of GS-9883 versus Triumeq in HIV+, Treatment-Naïve Adults

Trial Number: GS-US-380-1489

Description: A Phase 3, randomized, double-blind study to evaluate the safety and efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 infected, antiretroviral treatment-naïve adults

Double-Blind Study to Evaluate Safety and Efficacy of GS-9883 versus Tivicay plus F/TAF in HIV+, Treatment-Naïve Adults

Trial Number: GS-US-380-1490

Description: A Phase 3, randomized, double-blind study to evaluate the safety and efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 infected, antiretroviral treatment-naïve adult

Double-Blind Study to Evaluate the Safety and Efficacy of Switching from Dolutegravir and ABC/3TC (or a Fixed-Dose Combination of ABC/DTG/3TC) to a Fixed-Dose Combination of GS-9883/F/TAF

Trial Number: GS-US-380-1844

Description: A Phase 3, randomized, double-blind study to evaluate the safety and efficacy of switching from a regimen of Dolutegravir and ABC/3TC, or a fixed-dose combination (FDC) of ABC/DTG/3TC,  to a FDC of GS-9883/F/TAF in HIV-1 infected subjects who are virologically suppressed

Double-Blind Switch Study to Evaluate F.TAF in HIV-1 Infected Subjects who are Virologically Suppressed

Trial Number: Protocol GS-US-311-1717

Description: A Phase 3b, randomized, double-blind, switch study to evaluate F/TAF in HIV-1 infected subjects who are virologically suppressed on regimens containing ABC/3TC

Switch Study to Evaluate D/C/F/TAF, Once-Daily versus Staying on a Boosted Protease Inhibitor Regimen

Trial Number: TMC114IFD3013

Description: A Phase 3, randomized, active-controlled, open-label study to evaluate switching to a darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) once-daily, single-tablet regimen versus continuing the current regimen consisting of a boodted protease inhibitor (bPI) combined with emtricitabine/tenofovir disproxil fumerate (FTC/TDF) in virologically-suppressed, human immunodeficiency virus, type-1 (HIV-1) infected subjects

Hepatitis C Treatment SVR Registry

Trial Number: GS-US-248-0122

Description: A long term follow-up registry for subjects who achieve a sustained virologic response to treatment in gilead-sponsored trials in subjects with Chronic Hepatitis C infection (rollover study).

The Immunopathogenisis of HIV

Description: Sponsored by The Wistar Institute


The following clinical trials are ongoing at the YHEP Youth Health Center and currently enrolling patients:

Social Support as a Facilitator to Adherence to HIV Pre-Exposure Prophylaxis Among Adolescents and Young Adults

Note: Please see a PrEP coordinator to see if you qualify.


A Demonstration of PrEP Counseling and Administration in Two Family Planning Settings
Note: This study is enrolling cis and transgender women.


For more information on any of the clinical trials listed, please contact the Research Department at 215-525-8695.

Program Information

  • Phone: 215-525-8695

Research

Spotlight On

Karam Mounzer, MD

Dr. Mounzer identified two major gaps in the care of patients with HIV/hepatitis C (HCV) co-infection, and the complexity of multidrug-resistant HIV treatment. He is involved with many clinical trials focusing on drug development and better understanding of HIV immunopathogenesis with the Wistar Institute. He is involved in teaching and mentoring fellows, residents and students.

Learn More about Spotlight On
Karam Mounzer, MD

Pediatric and Adolescent Health Center

FIGHT Pediatrics and Adolescent Health Center - Dr. Mario Cruz
This DECEMBER Philadelphia FIGHT will be opening a new Pediatric and Adolescent Health Center dedicated to providing high quality, comprehensive, primary care to address the physical, emotional and sexual health needs of inner-city children and youth from birth through age 24.